S
uicide was the 10th leading cause of death in the United States in 2009, accounting for 36 897 deaths with an age-adjusted rate of 11.8 per 100 000 persons (1, 2) . It accounted for more than 1.4 million years of potential life lost before age 85 years (3). Suicide attempts and death rates vary substantially by sex; age; race; and other risk factors, such as psychiatric disorders (4 -7), prior suicide attempts (8 -11) , a history of nonsuicidal self-harm (7) , and a serious adverse childhood experience (12) (13) (14) (15) . Individual risk factors have a limited ability to predict suicide in a person at a particular time, but risk for a suicide attempt and death increases with multiple risk factors (covering psychosocial, biomedical, and developmental realms) and high levels of distress (16, 17) .
Thirty-eight percent of U.S. adults who completed suicide visited their primary care providers in the prior month; this rate was even higher (50% to 70%) in older adults (18) . Nearly 90% of suicidal youth had primary care visits during the previous 12 months, compared with 70% to 80% of nonsuicidal youth (19, 20) . Screening tools that are accurate and feasible for use in primary care could represent an important opportunity to identify persons at increased risk for suicide so that it can be prevented through appropriate treatment.
In 2004, the U.S. Preventive Services Task Force (USPSTF) concluded that evidence was insufficient to recommend for or against routine screening by primary care clinicians to detect suicide risk in the general population (I statement). That review found limited evidence that screening tests can reliably detect suicide risk in primary care populations (21) . A large body of evidence (33 randomized, controlled trials and 2 cohort studies) examined the effects of treatment on suicide attempts and suicide deaths in adolescents or adults.
Few trials showed benefit of treatment, and many were underpowered for these rare outcomes. Evidence also showed that nonpharmacologic treatment could reduce depressive symptoms and suicidal ideation in high-risk older adolescents and adults. Evidence was lacking on harms of screening and treatment.
guide our work (Appendix Table 1 , available at www .annals.org). Our full report describes the methods in detail (22) .
Data Sources
We considered all studies from the previous review for inclusion. We searched MEDLINE, PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials for studies published between January 2002 and 17 July 2012 to bridge and update from the previous review. We handsearched bibliographies of relevant reviews and searched Web sites of government agencies and professional organizations to identify relevant research published outside of peer-reviewed journals. We also conducted a surveillance search of MEDLINE through December 2012 to identify additional screening trials.
Study Selection
Two investigators independently reviewed the abstracts and articles against specified inclusion and exclusion criteria. We resolved disagreements through consultation with the larger project team. We included Englishlanguage studies in general primary care or specialty mental health populations (or similar populations) of any age. We also included studies limited to patients with depression, substance misuse, posttraumatic stress disorder, or borderline personality disorder. We excluded studies limited to patients with other mental health conditions.
For questions related to harms and benefits of screening or treatment, we included randomized and nonrandomized clinical trials. To address effects of treatment, we included trials of behavior-based or pharmacologic treatment with a primary aim of reducing suicide deaths, suicide attempts or self-harm, or suicidal ideation. We included studies of screening instrument accuracy that reported sensitivity, specificity, or related statistics of brief screening instruments to detect current increased suicide risk (usually suicidal ideation) relative to a reference standard. The reference standard had to be a more in-depth assessment of suicide risk by a trained mental health professional or a trained interviewer using a standardized instrument to determine whether suicide risk was increased. We would have included suicide attempts in the immediate period after screening (for example, 1 month) as a gold standard if we had found any studies that did this. We also would have included comparative cohort studies addressing harms of pharmacologic treatment in suicidal populations if we had found any.
Data Extraction and Quality Assessment
One investigator abstracted data from all included studies into a standard evidence table, and a second investigator checked the data for accuracy. Two investigators independently assessed the methodological quality of each study by using predefined design-specific quality criteria based on methods developed by the USPSTF (23) . We supplemented these criteria with the Quality Assessment of Diagnostic Accuracy Studies tool (24) to evaluate the quality of diagnostic accuracy (screening) studies, resulting in a rating of good, fair, or poor. We resolved disagreements in quality assessment through discussion and, if necessary, consultation with a third reviewer. We excluded poorquality trials.
Data Synthesis and Analysis
For all key questions, we created results tables with important study characteristics. We critically examined these tables to identify the range of results and potential associations with effect size. We examined trials limited to adolescents or limited to older adults separately from other adult trials.
For key questions 4 and 5 only, we conducted random-effects meta-analyses to estimate the effect size of suicide prevention interventions on suicide attempts or self-harm, suicidal ideation, and depression. We used Stata, version 11.2 (StataCorp, College Station, Texas), for all statistical analyses. Risk ratios were analyzed for suicide attempts. All trials reported at least 1 suicide attempt or self-harm episode in each intervention group, so no correction for empty cells was needed. We analyzed standardized mean differences (SMDs) in change from baseline for the continuous outcomes (suicidal ideation and depression). We calculated SDs of change from baseline by using a standard formula (25) .
We assessed the presence of statistical heterogeneity among the studies by using standard chi-square tests and the I 2 statistic (26). We applied the Cochrane Collaboration (27) rules of thumb for interpreting I 2 (probably unimportant, Ͻ40%; moderate, 30% to 60%; and substantial, 50% to 90%) and Cohen (28) rules of thumb for interpreting effect sizes (small, 0.2 to 0.5; medium, 0.5 to 0.8; and large, Ն0.8).
Role of the Funding Source
This research was funded by the Agency for Healthcare Research and Quality (AHRQ). The AHRQ staff provided oversight for the project and assisted in external review of the companion draft evidence synthesis but had no role in study selection, quality assessment, synthesis, or development of conclusions. The investigators are solely responsible for the content of the manuscript and the decision to submit for publication.
A subset of 12 of these trials also reported on adverse events or a (statistically nonsignificant) paradoxical increase in suicide attempts, which is discussed under key question 6 (36, 40, 41, 49, 51, 55-57, 66, 73, 76, 77) .
Benefits of Screening (Key Question 1)
We identified 1 short-term, fair-quality trial (n ϭ 443) that addressed key question 1. This trial found no clear short-term (that is, within 2 weeks) benefit of screening (29) . It was published after the 2004 USPSTF review on this topic and thus was not included in the previous review.
Screening Instrument Accuracy (Key Question 2)
Appendix Table 2 (available at www.annals.org) shows data from the 4 studies that reported the accuracy of screening instruments for identifying persons at increased risk for suicide (30 -33) . Two of these trials were conducted in adult or older adult primary care populations (32, 33). One study (the only diagnostic accuracy study also included in the 2004 review) examined the clinical utility of 3 suicide-related items in primary care patients aged 18 years or older with prescheduled appointments for any reason (n ϭ 1001) (32).
Items had sensitivities of 83% to 100% and specificities of 81% to 98% relative to a nurse-administered structured interview on the same day. The positive predictive values were low, ranging from 6% to 30%. Accuracy was lower in the study of the Geriatric Depression ScaleSuicidal Ideation subscale in general primary care patients aged 65 years or older (n ϭ 626) (33) . The optimal cutoff yielded a sensitivity and specificity of 80% for suicidal ideation during the previous 2 weeks, and the positive predictive value was fairly low (33%).
Two trials reported instrument accuracy in adolescent samples (combined n ϭ 799). Although these studies used different instruments and approaches to assemble their samples, both represented high-risk groups that had 22% to 27% prevalence of suicidal ideation or behavior. In these studies, sensitivity ranged from 52% to 87% and specificity ranged from 60% to 85%. These results are generalizable only to high-risk populations.
Harms of Screening (Key Question 3)
Three trials reported on potential adverse effects of screening (all published since the previous review). None identified serious adverse effects of screening (29, 34, 35 
Psychotherapy
Thirty-one trials investigated a specific psychotherapeutic treatment approach, generally compared with usual care. Nineteen were conducted in adults (37, 38, 41, 44, 47, 50 -52, 54 -56, 58 -60, 62-65, 67) , and 12 were conducted in adolescents (72-81, 83, 84). Most psychotherapy trials were done in high-risk populations, usually identified because these persons had a recent suicide attempt or selected mental health disorders (for example, borderline personality disorder) and a history of suicide attempts. The only study that identified patients through populationbased screening was conducted in Sri Lanka.
In adults, evidence was insufficient to evaluate the effect on suicide deaths, because only 6 of the 19 psychotherapy trials reported suicide deaths. Psychotherapy recipients had a 32% reduction in the likelihood of a suicide attempt or deliberate self-harm compared with usual care recipients (relative risk, 0.68 [95% CI, 0.56 to 0.83]; 11 trials; n ϭ 1583; I 2 ϭ 16.1%) (Figure 1 ). However, a single estimate of absolute benefit would be misleading, given the highly variable rate of suicide attempts or selfharm (15% to 71% of control group participants had a suicide attempt or self-harm episode at follow-up). When the trials with the most extreme suicide attempt rates were excluded (38, 50, 54, 55) , absolute differences ranged from a low of 46% in the control group and 39% in the intervention group (65) to a high of 47% in the control group and 23% in the intervention group (59) .
Psychotherapy did not show greater improvement than usual care for suicidal ideation (SMD, Ϫ0.10 [CI, Ϫ0.27 to 0.06]; 8 trials; n ϭ 964; I 2 ϭ 26.3%) (Figure 2) , and most trials reported reduced suicidal ideation in both intervention and control groups. Psychotherapy had a small beneficial effect on depression relative to usual care (SMD, Ϫ0.37 [CI, Ϫ0.55 to Ϫ0.19]; 12 trials; n ϭ 1653; I 2 ϭ 60.5%) (Figure 3) . Other outcomes were sparsely reported and had mixed results.
In adolescents, we could not determine the effects of suicide prevention treatment on deaths because only 1 death occurred in the 3 trials reporting this outcome. Psychotherapy did not reduce suicide attempts in adolescents at 6 to 18 months (relative risk, 0.99 [CI, 0.75 to 1.31]; 9 trials; n ϭ 1331; I 2 ϭ 49.1%) (Figure 1) . The CI of the pooled effect was wide, ranging from a 25% reduction in risk to a 31% increase in risk for suicide attempts.
The absolute proportion of participants with a suicide attempt or self-harm episode varied greatly across trials, as did the difference between groups. For example, in the 3 trials reporting suicide attempts or self-harm in 20% to 23% of control group participants, the proportion of youth in the intervention groups with suicide attempts or selfharm ranged from 11.4% to 36.1% (72, 78, 84). Given the wide range of results, we cannot rule out the possibility of harm (or benefit) on the basis of existing evidence.
Psychotherapy had no beneficial effect on suicidal ideation beyond usual care (SMD, Ϫ0.22 [CI, Ϫ0.46 to 0.02]; 6 trials; n ϭ 629; I 2 ϭ 41.2%) ( Figure 2) ; both the psychotherapy and usual care groups generally showed substantial improvement. Psychotherapy had a small beneficial effect on depression (SMD, Ϫ0.36 [CI, Ϫ0.63 to Ϫ0.08]; 6 trials; n ϭ 631; I 2 ϭ 53.6) (Figure 3) . Although statistical heterogeneity was high, all effects suggested that psychotherapy benefited persons with depression (but most effects were not statistically significant). Other health outcomes were sparsely reported and rarely showed beneficial effects for the interventions.
Among psychotherapy studies, we found no clear predictors of effect size other than target age (adults vs. adolescents), where trials in adults more consistently showed larger beneficial effects than those in adolescents. Among adolescent trials, limited data suggested that interventions targeting parents and youth, either separately or together, seemed to be more beneficial than those targeting only adolescents.
Enhanced Usual Care
We defined trials of "enhanced usual care" as those that attempted to improve the quality or format of recommended treatment (in primary or specialty care) or patient adherence to usual care while providing little to no direct therapeutic counseling or specific prescription for psychotherapy. Treatments varied widely, from mail-only to case management interventions, but most involved considerably less contact with patients than psychotherapy. One enhanced usual care trial was limited to adolescents and young adults (aged 15 to 24 years) (82), 2 were limited to older adult primary care patients (42, 71) , and the remain- Weights are from random-effects analysis. CB ϭ cognitive behavioral; D ϭ dialectical; DG ϭ developmental group; DSH ϭ deliberate self-harm; ODT ϭ other therapy, direct; OTND ϭ other therapy, nondirect; P ϭ psychodynamic; PS ϭ problem solving; SA ϭ suicide attempt.
ing trials included wide age ranges covering primarily adults. Most trials targeted participants who had an emergency department visit or inpatient stay related to a suicide attempt or self-harm. However, 3 trials were conducted in primary care settings, including both trials in older adults. PROSPECT (Prevention of Suicide in Primary Care Elderly: Collaborative Trial) addressed only depressed older adults (aged 60 to 94 years) and was the sole trial that used primary care-based screening for depression in the United States to identify eligible participants (42) . The other trial of older adults was a large cluster randomized trial (patients were randomly assigned at the level of provider) that included all patients older than 60 years on the panels of participating providers; this trial thus was not limited to patients who screened positive for suicidal ideation or had known risk factors for suicide, but was representative of a general Australian primary care population (71) .
The third trial with high applicability to primary care was a nonrandomized, population-based intervention trial that compared intervention and control regions of the county in Hungary with the highest suicide rates. This trial reported suicide rates per 100 000 persons as its outcome, rather than following an identified sample (70) . It involved a 5-year provider-education intervention that also offered free consultation and a depression clinic for referral.
Although 7 of the 17 enhanced usual care trials reported deaths, only 1 fair-quality trial reported significant group differences. This fairly large trial (n ϭ 843) sent participants 24 letters over 5 years expressing concern and encouraging treatment and reported a 49% reduction in suicide deaths at 2-year follow-up (1.8% in the intervention group vs. 3.5% in the control group; 1-tailed P ϭ 0.043) (61) . The large population-based trial in primary care practices seemed sufficiently powered to examine suicide deaths and found no reduction in suicide (70) . Aside from this population-based trial, very few deaths occurred across the remaining trials, and deaths were frequently not reported so we could not conclude that suicide deaths decreased. Weights are from random-effects analysis. CB ϭ cognitive behavioral; D ϭ dialectical; DG ϭ developmental group; OTND ϭ other therapy, nondirect; P ϭ psychodynamic; PS ϭ problem solving; SMD ϭ standard mean difference.
Thirteen of the 17 adult trials of enhanced usual care reported on suicide attempts, and all but 1 (53) found no difference in suicide attempts between 4 and 24 months (relative risk, 0.91 [CI, 0.80 to 1.02]; 13 trials; n ϭ 6592; I 2 ϭ 0.0%) (Figure 4) . These results are consistent with a small to moderate (20% at most) decrease in suicide attempts or no effect, compared with suicide attempt rates in the control groups ranging from 1% to 30% at 4 to 24 months.
Other health and intermediate outcomes were sparsely reported. The trials in older primary care patients reduced suicide attempts by 20% to 23% (42, 71) , but the results were significant only in the larger trial (71).
Medication
We included 1 fair-quality, placebo-controlled trial of lithium to prevent suicide in patients with depressionspectrum disorders and a recent suicide attempt (167 randomly assigned patients) (57) . Retention in this trial was low (only 31% of participants remained at the final 13-month follow-up). Although all 3 suicide deaths in the study occurred in placebo recipients, the groups did not differ in cumulative survival without a suicide attempt (hazard ratio, 0.517; P ϭ 0.21, adjusted for age, sex, and prior suicide attempts) or suicidal ideation.
Harms of Treatment (Key Question 6)
Although no harms were identified in any of the adult trials, 4 of the 12 trials reporting suicide attempts in adolescents reported statistically nonsignificant increases in suicide attempts of 22% to 113% (73, 76, 77, 82) . The possibility of harm cannot be ruled out in treatment of currently or recently suicidal adolescents.
The trial of lithium treatment reported that 13% of the lithium recipients withdrew from the study because of adverse effects, compared with 2% of placebo recipients. However, the statistical significance of this difference was not reported (57) . Overall withdrawal rates for any reason were similar between groups. Specific adverse effects were not reported. Weights are from random-effects analysis. CB ϭ cognitive behavioral; D ϭ dialectical; DG ϭ developmental group; OTND ϭ other therapy, nondirect; P ϭ psychodynamic; PS ϭ problem solving; SMD ϭ standard mean difference.
DISCUSSION
Suicide risk can be difficult to accurately assess because some persons may attempt to conceal suicidal thoughts (creating false-negative results on screening) and some may express suicidal thoughts without serious intention to kill themselves (creating false-positive results on screening) (113) . Even in high-risk populations, suicide is comparatively rare. Furthermore, the known risk factors associated with suicide are relatively common and individually not very strong predictors of suicide, even in persons at high risk. This combination of factors makes accurately predicting who will die by suicide on the basis of known risk factors very difficult. Nonetheless, suicide prevention is of high national importance, so it is critical to know whether primary care-based screening is likely to help reduce suicide in the United States by identifying patients in need of treatment and referring them to appropriate care. The Table summarizes the evidence from this review for all key questions.
Summary of Findings Screening
Although screening instruments have been developed for quick risk assessment, few studies have reported diagnostic accuracy characteristics of sensitivity, specificity, or related statistics relative to an interview with a clinician or other trained questioner. Minimal evidence (2 studies) suggested that screening tools can identify adults and older adults in primary care who are at increased risk for suicide, although these tools produce many false-positive results. Data on the accuracy of screening were even more limited in adolescents. Neither instrument performed well in adolescents, and the screening populations in which they were tested had relatively poor applicability to general primary care patients.
An important limitation of these data is the unknown accuracy of a full clinical interview in predicting suiciderelated events, which are relatively rare and inherently difficult to predict (17) . Instrument accuracy aside, we identified minimal data that examined whether suicide risk screening increased or decreased the likelihood of suicidality or other distress. Our results are consistent with those of an earlier review of suicide screening in adolescents, which concluded that data were very limited and future research was essential to determine whether and how screening can reduce suicide in young persons (114) .
Treatment in Adults
Although the included studies involved too few deaths to determine whether a particular treatment reduced the risk for suicide deaths, they provided useful evidence about Fair One of 7 trials found reduced risk for death at 2-y follow-up (1.8% in intervention group vs. 3.5% in control group) in participants who were sent periodic letters expressing interest in their well-being and among persons who refused treatment after a suicide attempt, but effects were reduced and no longer significant beyond 2 y (61). Reductions in suicide attempts or other health outcomes were generally not seen. Suicidal ideation and depression were rarely reported. NA High: one done in general primary care patients (71); the other identified participants through primary screening for depression (42) Fair Primary care-based intervention in depressed older adults that included a care manager showed benefits for depression and mixed results for suicidal ideation but no benefit for suicide deaths, attempts, or nonsuicidal deaths (42) . Education and training for providers reduced the risk for suicide attempts and ideation combined by 20% in a general primary care population of older adults but had no effect on depression (71 No trials directly reported harms; 4 of 11 trials related to key questions 4 and 5 reported statistically nonsignificant increases of 22% or more in suicide attempts or self-harm. The trial with the largest increase was small (n ϭ 31 with follow-up) and had few events but reported 22% to 33% increases in suicide attempts in the remaining 2 trials (73).
attempts. Combined assessment of all psychotherapy studies found that psychotherapy targeting suicide prevention reduced the risk for attempts by an estimated average of 32%. Psychotherapy also showed small beneficial effects on depression, although other beneficial outcomes were sparsely reported or showed no consistent group differences. Interventions that primarily focused on enhancing usual care had little effect on suicide deaths, suicide attempts, or related outcomes. The participants in the included adult treatment trials who reported suicide attempts were at high risk for suicide, usually based on a history of multiple attempts, which resulted in a very high incidence of suicide attempts (for example, 11% to 68% in the control groups of the psychotherapy trial). This finding contrasts with the screening accuracy studies that were done in general primary care patients, where attempt rates are substantially lower (probably Ͻ1% over 1 year) (115) . Thus, the indirect evidence linking screening accuracy with benefits of treatment is not good.
There are several possible explanations for why psychotherapy seemed to be effective in adults, whereas practice-based approaches or other enhanced usual care interventions were not. First, the care provided in enhanced usual care trials was generally less time-intensive than that provided in the psychotherapy trials, which may be associated with smaller effects. In addition, the enhanced usual care trials may have included slightly lower-risk samples than the psychotherapy trials, as evidenced by a smaller proportion of control group participants who attempted suicide at follow-up (0.5% to 28% of control participants).
Alternatively, usual care may have been more effective in these studies, which would also attenuate the effect (but which we could not examine with available evidence). Assuming that these interventions are less likely, on average, to be effective, some of the enhanced usual care interventions may nevertheless be useful components of a larger system-wide approach that includes psychotherapy.
We found minimal data on medication's effectiveness in preventing suicidal behavior. These data were limited to a single, short-term, fair-to poor-quality lithium trial that had high attrition. Lithium is commonly used for treating bipolar disorder and has been shown to reduce the risk for suicide in observational studies (116, 117) and in controlled trials of patients with unipolar and bipolar depression who were not necessarily suicidal, compared with placebo or other agents (pooled Peto odds ratio of randomized trials, 0.26 [CI, 0.09 to 0.77]) (118) . We found no studies on lithium use in patients identified through screening for suicidality. Lithium is associated with important adverse effects that were not described in the 1 trial included in this review (119 -121) .
Our findings were generally consistent with other recent reviews of treatment to prevent suicide or self-harm (122) (123) (124) (125) . Each of these recent reviews generally included similar bodies of research but grouped the trials differently. Nonetheless, they all found insufficient evidence for an effect on suicide deaths because of the small number of events. They also generally found small to moderate (usually nonsignificant) reductions in suicide attempts or selfharm, and all were limited by the included trials' sparse reporting of other outcomes. The most comprehensive of these reviews, published by the National Institute for Health and Clinical Excellence, concluded that psychological and psychosocial interventions may be effective compared with usual care. However, variations in populations, treatment methods, and comparison groups created uncertainty.
Treatment in Adolescents
Psychotherapy did not reduce the risk for suicide attempts in adolescents in contrast to adults. Data did not allow us to rule out the possibility that the risk for suicide attempts was paradoxically increased. Psychotherapy showed small beneficial effects on depression for adolescents, as it did for adults. Other outcomes either showed no consistent beneficial effects or were sparsely reported.
The research on iatrogenic suicidality related to antidepressants suggests that adolescents react differently from adults to pharmacologic treatment (126) . Research also suggests that risk factors and methods of committing suicide differ between younger versus older teenagers (127). Thus, different age groups seem to have different treatment needs and risks. The evidence base in adolescents is still small, and few approaches have been replicated. Replication is important, as shown by the trials of developmental behavior therapy in this review; beneficial results in a first trial (80) were not replicated in 2 subsequent good-quality trials (75, 77) . Overall, our findings were consistent with the National Institute for Health and Clinical Excellence review, in which only 1 trial showed a beneficial effect in adolescents (125).
Psychotherapy trials primarily involved high-risk youth, most with a recent suicide attempt or acute suicidal ideation. These samples are consistent with those in the screening studies but may have low applicability to youth identified through primary care screening. Suicidal youth need treatment, but caution, close monitoring, and care coordination are also warranted (128) . These trials suggest that active parental involvement in treatment may be important. Further research is urgently needed.
Limitations
One important limitation is that most of the treatment literature was in high-risk populations, so the generalizability of these results to screening-detected populations is unknown. In addition, there was very little evidence on the effectiveness of treatment in older adults and racial or ethnic minorities. Differences in suicide rates among ethnic groups suggest that cultures vary, both in motivation for and meaning of suicide; thus, culturally tailored riskbased screening and interventions may be important (129) .
The lack of power and reports of suicide death is another important limitation. Suicide attempts and self-harm are not good surrogates for suicide death. As a result, we cannot assume that the reduced attempts seen with psychotherapy interventions will decrease the number of deaths (130). Because suicide death is relatively rare and predicting such deaths is difficult, very large collaborative trials are probably required for sufficient power to see an effect on suicide deaths (131) . For example, if all participants in all psychotherapy trials that reported suicide deaths were treated as a single study that found a 57% reduction (0.62% in the intervention group vs. 1.44% in the control group), 4 times the number of actual participants would be needed to achieve statistical significance.
Power would probably be even more dramatically limited in studies of screening-detected patients. Assuming an annual suicide rate of 100 per 100 000 persons (twice as high as that of older white men, who have the highest rates of any age, sex, or racial subgroup) and the ability of a treatment to reduce suicide by 40%, more than 83 000 persons per group would be required to generate a statistically significant result. Thus, building a coherent chain of evidence from broad population-based screening through treatment to reduce suicide deaths will be difficult, because treatment studies will necessarily be limited to very highrisk groups in order to have sufficient power to detect a treatment effect.
Conclusion
Suicide prevention is a topic of high national importance in which primary care providers may have a role. Although evidence was limited, primary care-feasible screening tools could probably identify adult patients at increased risk for suicide who may need treatment. A larger body of evidence showed that psychotherapy can reduce the risk for suicide attempts in high-risk populations.
Unfortunately, whether similar benefits would be found in screening-detected patients is unknown. There was little evidence on the accuracy of screening in adolescents, and what little data are available showed that treatment did not demonstrate a positive effect. Results in adolescents also did not rule out the possibility of harm (that is, increased suicide attempts) with some forms of psychotherapy. More research on how to effectively identify and treat adolescents at increased risk for suicide is urgently needed. There is also a need for research on the effect of psychotherapy to prevent suicide attempts in primary care patients who screen positive for suicide risk, as well as whether treatments actually lead to lower suicide death rates, even in high-risk populations. Monthly postcards for 12 mo, expressing interest in the person's well-being, reminding him or her about previously identified sources of help, and describing 1 of 6 rotating self-help strategies (e.g., physical activity, books, and Web sites) 0 CBT ϭ cognitive behavioral therapy; C-CARE ϭ Counselors Care, Assess, Respond, Empower; DSH ϭ deliberate self-harm; ED ϭ emergency department; GP ϭ general practitioner; HADS ϭ Hospital Anxiety and Depression Scale; NA ϭ not applicable; NR ϭ not reported; P-CARE ϭ Parents Care, Assess, Respond, Empower; PCP ϭ primary care provider; PHQ-9 ϭ Patient Health Questionnaire-9; SA ϭ suicide attempt. * In the past 3 mo. † Participants were parasuicidal. ‡ Median number of self-mutilation acts. § Self-poisoning. Previous treatment for suicide attempt. ¶ Combined outcome of suicide attempts and suicidal ideation. ** 2 regions were similar in proportion of women (52%) and older residents (22%). † † 4 or more attempts in the past 3 y. ‡ ‡ In the past 12 mo. § § In the past 6 mo. Median number of lifetime "parasuicide" episodes. ¶ ¶ In the past month.
